NYB.AI, an AI-driven drug discovery platform, has gained recognition at NVIDIA GTC Taiwan 2026, showcasing its innovative potential in the life sciences sector.
Developed by Nanyang Biologics, NYB.AI was highlighted in the opening showcase video at the event, which featured select companies from the NVIDIA Inception ecosystem. This recognition underscores the growing global interest in integrating artificial intelligence with biology and high-performance computing to enhance drug discovery processes. NYB.AI’s capabilities in accelerating hypothesis generation and molecular screening position it as a significant player in the evolving landscape of AI in scientific research.
Ravindran Govindan, Chairman of Fischer Medical Ventures Limited, emphasized the importance of this initiative for India’s pharmaceutical ecosystem. He noted that the initial focus will be on distributing AI-enabled discovery tools and nutritional wellness products, particularly in regions with active research. This partnership aims to leverage India’s scientific strengths and foster long-term innovation in drug development.
Fischer Medical Ventures has been appointed as the exclusive distributor for selected products from the Nanyang Biologics ecosystem in India, with plans to introduce scientifically developed nutritional formulations. The broader strategy includes exploring pathways to integrate AI-powered molecular discovery into India’s pharmaceutical sector, aiming to support research institutions and pharmaceutical companies in early-stage drug discovery.
This collaboration envisions a future where AI technologies are seamlessly integrated into research and development, enhancing drug discovery and fostering talent development in computational biology within India. By building strategic partnerships and focusing on regulatory compliance, the initiative aims to create a robust ecosystem for innovation in the life sciences.